Variables |
Anakinra (n=139) |
SoC (n=114) |
p
value (OR) |
Anakinra (n=88) |
SoC (n=88) |
p
value (OR) |
Age, years, median (IQR) |
71 (25) |
65.5 (23) |
0.09 |
70 (29) |
66.5
(24) |
0.6 |
Gender, male, n (%) |
72 (51.8) |
45 (39.5) |
0.05
(3.8) |
40 (45.5) |
41 (46.6) |
0.9 |
Duration of hospitalisation (days), median (IQR) |
11 (12) |
9 (7.3) |
0.03 |
10 (13) |
10 (9) |
0.8 |
Comorbidities, n (%) |
|
|
|
|
|
|
Diabetes mellitus |
36/137 (26.3) |
39 (34.2) |
0.17 |
27 (30.7) |
29
(33) |
0.7 |
Hypertension |
79/135 (58.5) |
64 (56) |
0.7 |
49/86 (57) |
53 (60.2) |
0.7 |
Coronary heart disease |
24/135 (17.8) |
24 (21) |
0.5 |
19/86 (22) |
19
(21.6) |
0.9 |
Chronic renal failure |
28 (20) |
6 (5.3) |
0.001 (11.9) |
15/75 (19.2) |
22 (25) |
0.4 |
Chronic obstructive lung disease |
22/136 (16.2) |
19 (16.7) |
0.9 |
14/86 (16.3) |
14 (16) |
1 |
Malignancy |
16/138 (11.6) |
8 (7) |
0.2 |
6 (6.8) |
8 (9.1) |
0.6 |
Vaccination history |
44/86 (51.2) |
26/63 (41.3) |
0.2 |
31/58 (53.4) |
18/48 (37.5) |
0.1 |
Disease severity, n (%) |
|
|
|
|
|
|
NIH score 3 (severe) |
54 (38.8) |
68 (59.6) |
0.001
(10.9) |
36 (41) |
46 (52) |
0.1 |
NIH score 4 (critical) |
85 (61.2) |
46 (40.4) |
|
52 (59) |
42 (48) |
|
Vaccination history, median (IQR) |
2 (1) |
2 (0) |
0.9 |
3 (1) |
2
(1.5) |
0.13 |
mcHIS score, median (IQR) |
3 (1) |
3 (3) |
<0.001 |
3 (2) |
3 (2) |
0.5 |
Laboratory results |
|
|
|
|
|
|
Neutrophil to lymphocyte ratio, median (IQR) |
6.8 (8) |
4.4 (4.44) |
0.002 |
6.9 (8.2) |
4.6 (5.4) |
0.06 |
Hemoglobin (g/L), mean±SD |
13.2±2.2 |
13.2±2 |
0.6 |
13.3±2.3 |
13.2±2 |
0.5 |
Creatinine (mg/dL), median (IQR) |
0.9 (0.47) |
0.83 (0.52) |
0.5 |
0.84
(0.54) |
0.9 (0.68) |
0.4 |
Prokalsitonin (pg/dL), median (IQR) |
0.2 (0.46) |
0.16 (0.31) |
0.7 |
0.18 (0.43) |
0.18 (0.62) |
0.5 |
C-reactive protein (mg/L), median (IQR) |
|
|
|
|
|
|
1 |
116 (113) |
100.3 (100.3) |
0.4 |
115 (133) |
107 (107) |
0.9 |
2 |
148 (120) |
126 (88) |
0.012 |
141 (152) |
141.2
(90) |
0.7 |
3 |
11.4 (64) |
13.1 (91) |
0.5 |
10.4 (58.8) |
14.5 (101) |
0.2 |
Ferritin (pg/mL), median (IQR) |
|
|
|
|
|
|
1 |
393 (592) |
322 (423) |
0.076 |
334.5 (590.5) |
302 (371) |
0.16 |
2 |
714 (969) |
378 (660) |
<0.001 |
630 (811) |
495 (873) |
0.12 |
3 |
392 (590) |
268 (480) |
0.007 |
379 (427) |
313
(630) |
0.7 |
D-dimer (pg/mL), median (IQR) |
|
|
|
|
|
|
1 |
1.2 (1.1) |
0.85 (1.05) |
0.04 |
1.24 (1.14) |
1 (1) |
0.05 |
2 |
4.1 (12.2) |
2.25 (5) |
0.002 |
2.75 (14.8) |
2.7
(6.8) |
0.4 |
3 |
1.4 (4.1) |
1.14 (2.14) |
0.15 |
1.37 (3.3) |
1.2 (3.6) |
0.9 |
Lactate dehydrogenase (U/L), median (IQR) |
|
|
|
|
|
|
1 |
404 (220) |
414 (229) |
0.7 |
398.5 (219) |
399.5 (210) |
0.5 |
2 |
559 (266) |
408 (237) |
<0.001 |
570 (259) |
425 (269) |
<0.001 |
3 |
357 (231) |
334 (170) |
0.03 |
366.5 (204) |
345.5
(195) |
0.15 |
Outcomes, n (%) |
|
|
|
|
|
|
Severe infection |
19/128 (14.8) |
26 (22.8) |
0.1 |
13/82 (16) |
25
(28.4) |
0.05 (3.9) |
Pneumothorax |
3/134 (2.2) |
0 |
0.1 |
2/86 (2.3) |
0,00 |
0.15 |
Development of any thrombotic event |
7 (5) |
14 (12.3) |
0.038 (4.3) |
3 (3.4) |
14 (15.9) |
0.005
(7.9) |
Pulmonary thromboembolism |
4 (2.9) |
11 (9.6) |
0.023
(5.1) |
3 (3.4) |
11 (12.5) |
0.026 (5) |
Myocardial infarction |
3 (2.2) |
6 (5.3) |
0.2 |
0 |
6 (6.8) |
0.013 (6.2) |
ICU requirement |
55 (39.6) |
25 (22) |
0.003 (9) |
33
(37.5) |
24 (27.3) |
0.2 |
Mortality |
51 (36.7) |
27 (23.7) |
0.026 (5) |
30
(34.1) |
25 (28.4) |
0.4 |